Triple immune modulator therapy for aberrant hyperinflammatory responses in severe COVID-19

A dysregulated hyperinflammatory response is a key pathogenesis of severe COVID-19, but optimal immune modulator treatment has not been established. To evaluate the clinical effectiveness of double (glucocorticoids and tocilizumab) and triple (plus baricitinib) immune modulator therapy for severe CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Koh, June-Young, Ko, Jae-Hoon, Lim, So Yun, Bae, Seongman, Huh, Kyungmin, Cho, Sun Young, Kang, Cheol-In, Chung, Doo Ryeon, Chung, Chi Ryang, Kim, Sung-Han, Peck, Kyong Ran, Lee, Jeong Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139747/
https://www.ncbi.nlm.nih.gov/pubmed/37119951
http://dx.doi.org/10.1016/j.clim.2023.109628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139747/
https://www.ncbi.nlm.nih.gov/pubmed/37119951
http://dx.doi.org/10.1016/j.clim.2023.109628

Ejemplares similares